基石药业(02616.HK)「择捷美」治疗复发难治性结外NK/T细胞淋巴瘤新适应症上市申请获内地受理

AAFN2022-09-13

基石药业公布，继III期和IV期非小细胞肺癌适应症后，「择捷美」在内地申报第三项新适应症上市申请，获中国国家药品监督管理局受理并纳入优先审评，有望成为全球首个获批用於复发或难治性结外NK/T细胞淋巴瘤的肿瘤免疫治疗药物。集团指，是次「择捷美」治疗淋巴瘤的新适应症上市申请获得受理是基於GEMSTONE-201研究，该研究旨在评估「择捷美」作为单药治疗成人R/R ENKTL的有效性和安全性。「择捷...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2267828585?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-09-13 16:57","share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","id":"2267828585","market":"us","top_or_hot":-1,"title":"基石药业(02616.HK)「择捷美」治疗复发难治性结外NK/T细胞淋巴瘤新适应症上市申请获内地受理","media":"AAFN","content":"<div>\n<p>基石药业  公布，继III期和IV期非小细胞肺癌适应症后，「择捷美」在内地申报第三项新适应症上市申请，获中国国家药品监督管理局受理并纳入优先审评，有望成为全球首个获批用於复发或难治性结外NK/T细胞淋巴瘤的肿瘤免疫治疗药物。集团指，是次「择捷美」治疗淋巴瘤的新适应症上市申请获得受理是基於GEMSTONE-201研究，该研究旨在评估「择捷美」作为单药治疗成人R/R ENKTL的有效性和安全性。「择捷...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1213081&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n","source":"aastocks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>基石药业(02616.HK)「择捷美」治疗复发难治性结外NK/T细胞淋巴瘤新适应症上市申请获内地受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n基石药业(02616.HK)「择捷美」治疗复发难治性结外NK/T细胞淋巴瘤新适应症上市申请获内地受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-13 16:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1213081&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>基石药业  公布，继III期和IV期非小细胞肺癌适应症后，「择捷美」在内地申报第三项新适应症上市申请，获中国国家药品监督管理局受理并纳入优先审评，有望成为全球首个获批用於复发或难治性结外NK/T细胞淋巴瘤的肿瘤免疫治疗药物。集团指，是次「择捷美」治疗淋巴瘤的新适应症上市申请获得受理是基於GEMSTONE-201研究，该研究旨在评估「择捷美」作为单药治疗成人R/R ENKTL的有效性和安全性。「择捷...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1213081&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02616","symbol_name":"基石药业-B","start_time":0,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1213081&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","article_id":"2267828585","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2267828585","pubTimestamp":1663059445,"sourceInfo":{"source_id":"aastocks","name":"阿思达克财经"},"weMediaInfo":null,"summary":"基石药业  公布，继III期和IV期非小细胞肺癌适应症后，「择捷美」在内地申报第三项新适应症上市申请，获中国国家药品监督管理局受理并纳入优先审评，有望成为全球首个获批用於复发或难治性结外NK/T细胞淋巴瘤的肿瘤免疫治疗药物。「择捷美」先後被美国食品药品监督管理局和国家药品监督管理局药品审评中心，授予突破性疗法认定和纳入突破性治疗药物，用於治疗成人复发或难治性结外NK/T细胞淋巴瘤。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02616":"基石药业-B"},"translate_title":"Cornerstone Pharmaceutical (02616. HK) \"Zejiemei\" for the treatment of relapsed and refractory extranodal NK/T cell lymphoma was accepted by the mainland","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NK":1,"02616":0.9},"content_text":"基石药业  公布，继III期和IV期非小细胞肺癌适应症后，「择捷美」在内地申报第三项新适应症上市申请，获中国国家药品监督管理局受理并纳入优先审评，有望成为全球首个获批用於复发或难治性结外NK/T细胞淋巴瘤的肿瘤免疫治疗药物。集团指，是次「择捷美」治疗淋巴瘤的新适应症上市申请获得受理是基於GEMSTONE-201研究，该研究旨在评估「择捷美」作为单药治疗成人R/R ENKTL的有效性和安全性。「择捷美」先後被美国食品药品监督管理局和国家药品监督管理局药品审评中心，授予突破性疗法认定和纳入突破性治疗药物，用於治疗成人复发或难治性结外NK/T细胞淋巴瘤。(ek/w)~阿思达克财经新闻网址: www.aastocks.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2267828585"}